Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 food-effect and dose-escalation study of E7820 in unresectable solid tumors
NL-OMON36618Phase 1Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of e7820 in Nonhematologic neoplasms (4 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Effect of food on oral bioavailability of E7820, Maximum tolerated dose for once-daily dosing and 1 more. Started Jul 2011; status: active, not recruiting.
02
Drugs
e7820
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON36618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36618.